Clinical Trials

Carcinoma, Non-Small-Cell Lung

NCT00596648 2026-01-13

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

92 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

8 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03137771 2025-11-25

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

218 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT01186861 2025-11-18

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

205 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01221077 2025-11-18

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

88 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT00977470 2025-10-15

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

76 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

492 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT05442060 2025-08-03

EGFR

Phase 2 Recruiting

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02991651 2025-05-14

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Phase 1 Terminated

12 enrolled

Carcinoma, Non-Small-Cell Lung

NCT00983307 2025-04-30

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

17 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT00503971 2025-03-07

Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.

Phase 1/2 Terminated

33 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT00446225 2025-03-05

EURTAC

Phase 3 Completed

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02535338 2025-03-03

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

11 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02424617 2025-02-26

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

40 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT00708448 2025-02-13

Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients

26 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06071013 2025-01-23

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Phase 1/2 Recruiting

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02588261 2024-12-10

SOLAR

Phase 3 Terminated

530 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT02495233 2024-11-27

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Phase 1/2 Terminated

10 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT00739453 2024-11-20

A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)

GastrointestinalGenitourinaryThoracic

95 enrolled

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01306045 2024-10-01

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

647 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT02352948 2024-07-26

ARCTIC

Phase 3 Completed

597 enrolled 23 charts

Non - Small Cell Lung Cancer NSCLC

NCT00254384 2024-07-05

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03192501 2024-06-25

iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray

Recruiting

250 enrolled

Lung Neoplasms, Neoplasms

NCT03076164 2024-04-02

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

24 enrolled 8 charts

Adenocarcinoma of Lung, Lung Neoplasms

NCT02098954 2023-12-27

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Phase 2 Unknown

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03647592 2023-12-27

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05081674 2023-10-11

BLISS

154 enrolled

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT01068587 2023-08-04

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

31 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00750698 2023-07-06

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Phase 2 Terminated

8 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01104155 2023-06-22

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

123 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT04179890 2023-05-25

UpSwinG

Completed

462 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT02633189 2023-03-24

BEVERLY

Phase 3 Unknown

200 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT01859026 2023-01-19

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

43 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02039674 2022-11-08

MK-3475-021

267 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT01562028 2022-08-24

BELIEF

109 enrolled 20 charts